Guizhou Bailing Group Pharmaceutical Co., Ltd. (SHE:002424)
China · Delayed Price · Currency is CNY 5.00
+0.13 (2.67%)
Feb 27, 2026, 3:04 PM CST
SHE:002424 Revenue
Guizhou Bailing Group Pharmaceutical had revenue of 639.60M CNY in the quarter ending September 30, 2025, with 1.11% growth. This brings the company's revenue in the last twelve months to 3.15B, down -25.47% year-over-year. In the year 2024, Guizhou Bailing Group Pharmaceutical had annual revenue of 3.83B, down -10.26%.
Revenue (ttm)
3.15B
Revenue Growth
-25.47%
P/S Ratio
2.17
Revenue / Employee
478.52K
Employees
6,586
Market Cap
6.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.83B | -437.59M | -10.26% |
| Dec 31, 2023 | 4.26B | 722.84M | 20.42% |
| Jan 1, 2023 | 3.54B | 429.01M | 13.79% |
| Jan 1, 2022 | 3.11B | 23.24M | 0.75% |
| Dec 31, 2020 | 3.09B | 237.30M | 8.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HPGC Renmintongtai Pharmaceutical | 10.22B |
| Guizhou Xinbang Pharmaceutical | 5.73B |
| Shanxi Zhendong Pharmaceutical Co.,Ltd | 2.92B |
| Jinghua Pharmaceutical Group | 1.45B |
| Zhejiang AngLiKang Pharmaceutical CO.,LTD. | 1.45B |
| Teyi Pharmaceutical Group Co.,Ltd | 924.04M |
| Chongqing Pharscin Pharmaceutical | 786.51M |
| ChengDu ShengNuo Biotec | 638.35M |